Studying sequence and function of DNA has been in the focus of life sciences for decades, but now the interest of many researchers has turned to the RNA. Today, many scientists believe that RNA molecules, together with a variety of different proteins, play a regulatory or structural role in virtually all cellular processes. However, the mechanisms underlying these RNA-protein interactions are still largely unknown. A team of scientists from the Max Planck Institute for Molecular Genetics in Berlin has now successfully identified hundreds of proteins that interact with RNA molecules in the nucleus of human cells. The researchers present the first RNA interactome of a human nucleus and describe how they have identified the bulk of RNA-binding proteins in the nucleus of human cells, using their newly developed method of “serial RNA interactome capturing”.
For decades, proteins have been regarded as the main functional components in living cells. However, in recent years their paramount importance for cellular processes has been rivaled by the growing knowledge about the involvement of RNA molecules. RNA in the shape of messenger RNA (mRNA) and transfer RNA (tRNA) has been believed to act as a mere mediator between the DNA, carrying the genetic information, and the proteins, being the building blocks of the cell. But for a few years it has been shown now, that in addition to being a messenger for the genomic information, the RNA mediates several other functions. These non-coding functions of RNA include tasks in the regulation of gene transcription and protein production as well as the determination of the positions of other molecules within the cell.
Elucidating the interplay between proteins and RNA has therefore become crucial for understanding the molecular mechanisms of the development of organisms and the emergence of diseases.
A research group headed by Ulf Andersson Ørom at the Max Planck Institute for Molecular Genetics in Berlin has now for the first time created an overview of the numerous interactions between RNA molecules and proteins in a human nucleus. For this, the scientists had to modify the “RNA interactome capture technique” for analyzing RNA-protein interactions at first, so that they could use it to identify the RNA-protein interactions inside specific compartments of the cell, e.g., the nucleus. With the modified method, the researchers investigated the nuclei of a total of one billion cells in order to capture and catalogue all possible RNA-protein interactions in the nucleus.
“It has been particularly interesting for us that many of the discovered RNA-binding proteins do not only control the activity of genes and the fate of the resulting RNA molecules, but are also involved in the detection and repair of damaged DNA”, Ørom explains. DNA damage such as false or missing bases or breakage of one or both strands of the DNA double helix can occur as a consequence of reactive oxygen species, UV-radiation or other external or internal stimuli. DNA-damage occurs thousands of times each day within every cell in the body. The cell responds with a complex repair process involving numerous proteins and RNA molecules that specifically repair damaged DNA, thus maintaining the functionality of the cell.
“A role for RNA in the repair of damaged DNA has been suspected for some time, but how RNA can impact on this process has remained unknown”, says Ørom. “By identifying the protein factors that link RNA to the DNA damage response, this study contributes to a better understanding of these mechanisms.” The scientists hope that their findings will contribute to a better understanding of the emergence of human diseases and the development of new therapies against cancer.
Sourced through Scoop.it from: phys.org
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.